Opendata, web and dolomites

RheoCare SIGNED

Rheological Monitoring of Chronic Respiratory Diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RheoCare project word cloud

Explore the words cloud of the RheoCare project. It provides you a very rough idea of what is the project "RheoCare" about.

emergency    monitoring    remoulding    feasibility       rheometer    mucus    causing    reproducibility    diseases    block    demonstrated    software    airways    assessing    trials    forecast    choose    rheonova    2020    acute    exacerbation    china    personalised    healthcare    benefit    lower    care    strategy    80    respiratory    regarding    hospitalisations    technique    specificity    predicting    commercialised    chronic    attractive    exist    plan    efficiency    eight    treatments    clinical    5b    play    periodic    g8    point    segment    lung    attractively    cystic    capacity    supporting    spectrum    patient    techniques    biomarker    develops    rheology    irreversible    quantitatively    cf    first    commercialisation    protected    crises    fibrosis    robustness    plug    machine    mortality    group    rheocare    performance    structures    building    patients    infections    manipulation    antibioresistances    treatment    market    favouring    protocols    minutes    ip    automated    device    crisis    assesses    worldwide    accompanied    samples    priced    secretions    quantitative    consumables    phases    medical    patent    pulmonary    biomarkers    complete    ambition    24k   

Project "RheoCare" data sheet

The following table provides information about the project.

Coordinator
RHEONOVA SAS 

Organization address
address: 31 BOULEVARD AGUTTE SEMBAT
city: GRENOBLE
postcode: 38000
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RHEONOVA SAS FR (GRENOBLE) coordinator 50˙000.00

Map

 Project objective

Chronic respiratory diseases are expected to become the third cause of mortality worldwide by 2020. Patients experience periodic acute exacerbation phases favouring infections of the lower airways and causing irreversible loss of pulmonary capacity. These crises cannot be forecast with current techniques and require emergency hospitalisations, leading to healthcare costs (€24k per crisis) and antibioresistances due to wide-spectrum treatments. Among respiratory diseases, we choose to target cystic fibrosis (CF) in Europe as organised care structures pre-exist. CF also represents a very attractive market segment of $4.5B across the Group of Eight (G8). Rheonova develops a unique monitoring test based on the rheology of lung secretions (mucus). The RheoCare project will provide a dedicated plug-and-play rheometer, with a quantitative biomarker and a specificity above 80%, allowing a point-of-care CF monitoring test within 10 minutes as a first step towards personalised healthcare. Our four-patent-protected technique already assesses treatments efficiency and is commercialised to researchers. Phase 1 clinical trials have demonstrated the reproducibility and the robustness of our biomarkers. Two new clinical protocols (Phase 2) proceed in order to demonstrate the medical benefit for the patient, i.e. the reduction of hospitalisations by predicting the exacerbation phases and assessing treatment performance quantitatively. Within three years, Phase 3 clinical trials will support the commercialisation of the device in EU and China. We will address the medical market with an attractively-priced machine accompanied with specific consumables needed to test mucus samples. To support our ambition, we need to implement an automated sample manipulation device. Three priority tasks remain to complete the feasibility study: (i) remoulding the software, (ii) supporting our commercialisation plan, and (iii) defining the IP strategy regarding this new building block.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RHEOCARE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RHEOCARE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

GREEN WHS (2019)

NATURE FRIENDLY WATER HYDRAULIC STEERING SYSTEM

Read More  

CyreenApplication (2019)

Connecting Ad-Impressions with Purchase. The new advanced Advertisement at the point of sales.

Read More